Romain Paoli-Lombardo

Mr. Romain Paoli-Lombardo

Aix-Marseille University, Marseille, Provence-Alpes-Côte d’Azur, France
+1

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 September 2020 in European Journal of Medicinal Chemistry
Verified
Journal Article
Closed access
Cyril FersingCyril Fersing
Cyril Fersing
CBClotilde Boudot
Clotilde Boudot
CCCaroline Castera-Ducros
Caroline Castera-Ducros
EPEmilie Pinault
Emilie Pinault
SHSébastien Hutter
Sébastien Hutter
PVPatrice Vanelle
Patrice Vanelle

1 November 2020 in European Journal of Medicinal Chemistry
Verified
Journal Article
Closed access
Cyril FersingCyril Fersing
Cyril Fersing
CBClotilde Boudot
Clotilde Boudot
Romain Paoli-LombardoRomain Paoli-Lombardo
Romain Paoli-Lombardo
Nicolas PrimasNicolas Primas
Nicolas Primas
EPEmilie Pinault
Emilie Pinault
PVPierre Verhaeghe
Pierre Verhaeghe

13 August 2022 in Pharmaceuticals
Verified
Journal Article
Open access
PDF file
Romain Paoli-LombardoRomain Paoli-Lombardo
Romain Paoli-Lombardo
Nicolas PrimasNicolas Primas
Nicolas Primas
SBSandra Bourgeade-Delmas
Sandra Bourgeade-Delmas
SHSébastien Hutter
Sébastien Hutter
ASAlix Sournia-Saquet
Alix Sournia-Saquet
Vanelle PatriceVanelle Patrice
Vanelle Patrice
An antileishmanial structure–activity relationship (SAR) study focused on positions 2 and 8 of the imidazo[1,2-a]pyridine ring was conducted through the synthesis of 22 new derivatives. After being screened on the promatigote and axenic amastigote stages of Leishmania donovani and L. infantum, the best compounds were tested against the intracellular amastigote stage of L. infantum and evaluated regarding their in vitro physicochemical and pharmacokinetic properties, leading to the discovery of a new antileishmanial6-chloro-3-nitro-8-(pyridin-4-yl)-2-[(3,3,3-trifluoropropylsulfonyl)methyl]imidazo[1,2-a]pyridine hit. It displayed low cytotoxicities on both HepG2 and THP1 cell lines (CC50 > 100 µM) associated with a good activity against the intracellular amastigote stage of L. infantum (EC50 = 3.7 µM versus 0.4 and 15.9 µM for miltefosine and fexinidazole, used as antileishmanial drug references). Moreover, in comparison with previously reported derivatives in the studied series, this compound displayed greatly improved aqueous solubility, good mouse microsomal stability (T1/2 > 40 min) and high gastrointestinal permeability in a PAMPA model, making it an ideal candidate for further in vivo studies on an infectious mouse model.

25 April 2023 in Molbank
Verified
Journal Article
Open access
PDF file
Romain Paoli-LombardoRomain Paoli-Lombardo
Romain Paoli-Lombardo
Nicolas PrimasNicolas Primas
Nicolas Primas
CCCaroline Castera-Ducros
Caroline Castera-Ducros
IJInès Jacquet
Inès Jacquet
PRPascal Rathelot
Pascal Rathelot
Vanelle PatriceVanelle Patrice
Vanelle Patrice
In continuation of our research program to develop original synthetic methods using TDAE methodology on nitroheterocyclic substrates, we were able to generate for the first time a stable carbanion in position 2 of the 5-nitroimidazole scaffold. Starting from a 2-chloromethyl-4-phenylsulfonylmethyl-5-nitroimidazole intermediate, prepared by the vicarious nucleophilic substitution of hydrogen (VNS) reaction, we selectively introduced a N-tosylbenzylimine moiety at position 2 without reducing the sulfone at position 4, leading to the formation of N-[1-(2-chlorophenyl)-2-{1-methyl-5-nitro-4-[(phenylsulfonyl)methyl]-1H-imidazol-2-yl}ethyl]-4-methylbenzenesulfonamide in 47% yield. This new synthetic method using TDAE should allow access to new 2-substituted 5-nitroimidazole derivatives with various electrophiles such as carbonyls and other N-tosylbenzylimines.

1 February 2023 in Molbank
Verified
Journal Article
Open access
PDF file
Romain Paoli-LombardoRomain Paoli-Lombardo
Romain Paoli-Lombardo
Nicolas PrimasNicolas Primas
Nicolas Primas
SHSébastien Hutter
Sébastien Hutter
SBSandra Bourgeade-Delmas
Sandra Bourgeade-Delmas
CBClotilde Boudot
Clotilde Boudot
Vanelle PatriceVanelle Patrice
Vanelle Patrice
As part of our ongoing scaffold-hopping work on an antikinetoplastid 3-nitroimidazo[1,2-a]pyridine scaffold, we explored 3-nitroimidazo[1,2-b]pyridazine as a potential new antikinetoplastid series. Using conditions previously described by our lab, we obtained 6-chloro-3-nitro-2-[(phenylsulfonyl)methyl]imidazo[1,2-b]pyridazine with 54% yield. In vitro activity of this compound was evaluated against both the promastigote form of Leishmania donovani, the axenic amastigote form of Leishmania infantum and the trypomastigote blood stream form of Trypanosomabrucei brucei, and its influence on cell viability was assessed on the HepG2 cell line. However, despite good activity against the trypomastigote blood stream form of T. b. brucei (EC50 = 0.38 µM), it showed poor solubility in both HepG2 (CC50 > 7.8 µM) and L. infantum axenic amastigotes (EC50 > 1.6 µM) culture media, associated with a loss of activity against the promastigote form of L. infantum (EC50 > 15.6 µM).

30 March 2023 in Molbank
Verified
Journal Article
Open access
PDF file
Romain Paoli-LombardoRomain Paoli-Lombardo
Romain Paoli-Lombardo
Nicolas PrimasNicolas Primas
Nicolas Primas
SHSébastien Hutter
Sébastien Hutter
SBSandra Bourgeade-Delmas
Sandra Bourgeade-Delmas
CBClotilde Boudot
Clotilde Boudot
Vanelle PatriceVanelle Patrice
Vanelle Patrice
As part of our ongoing antikinetoplastid structure–activity relationship study focused on positions 2 and 8 of the 3-nitroimidazo[1,2-a]pyridine scaffold, we were able to introduce a phenylthioether moiety at both position 2 and position 8 in one step. Using a previously reported synthetic route developed in our laboratory, we obtained 6-chloro-3-nitro-8-(phenylthio)-2-[(phenylthio)methyl]imidazo[1,2-a]pyridine in 74% yield. The in vitro cell viability of this compound was assessed on the HepG2 cell line, and its in vitro activity was evaluated against the promastigote form of L. donovani, the axenic amastigote form of L. infantum and the trypomastigote blood stream form of T. b. brucei. It showed low solubility in HepG2 culture medium (CC50 > 7.8 µM), associated with weak activity against both the promastigote form of L. donovani (EC50 = 8.8 µM), the axenic amastigote form of L. infantum (EC50 = 9.7 µM) and the trypomastigote blood stream form of T. b. brucei (EC50 = 12.8 µM).